ABUS
NASDAQ · Biotechnology
Arbutus Biopharma Corp
$3.67
-0.39 (-9.61%)
Open$4.02
Previous Close$4.06
Day High$4.06
Day Low$3.62
52W High$5.45
52W Low$3.50
Volume—
Avg Volume2.04M
Market Cap734.77M
P/E Ratio4.80
EPS$0.78
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,296.5% upside
Current
$3.67
$3.67
Target
$51.25
$51.25
$34.47
$51.25 avg
$59.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 14.72M | 20.67M | 146.67M |
| Net Income | -34,996,874 | -44,237,621 | -16,611,843 |
| Profit Margin | -237.9% | -226.0% | -11.3% |
| EBITDA | -39,501,621 | -52,705,814 | -23,689,130 |
| Free Cash Flow | — | — | -19,958,595 |
| Rev Growth | -28.8% | -28.8% | -8.1% |
| Debt/Equity | 0.04 | 0.04 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |